Summary:
In adults with long-standing type 2 diabetes inadequately controlled, subcutaneous tirzepatide, a dual agonist of GIP and GLP-1 receptors significantly enhanced pancreatic islet function, improved insulin sensitivity, and facilitated substantial reductions in blood glucose, aiding many patients in achieving normoglycemia compared to placebo and semaglutide interventions.
| PICO | Description |
|---|---|
| Population | Adults with long-standing type 2 diabetes inadequately controlled, characterized by an inability to achieve normoglycemia through existing treatments. |
| Intervention | Subcutaneous tirzepatide, a dual agonist of GIP and GLP-1 receptors, administered as part of a phase 1, randomized, double-blind trial. |
| Comparison | Placebo and semaglutide interventions to evaluate the efficacy and physiological responses elicited by tirzepatide. |
| Outcome | Tirzepatide significantly enhanced pancreatic islet function and improved insulin sensitivity compared to placebo and semaglutide. The intervention also facilitated substantial reductions in blood glucose, aiding many patients in achieving normoglycemia. |
Source: Tim Heise, et al. “Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.” Read article here.
